Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | CTSS | P25774 | 6/20 | 0.42 |
| ▸ | CTSK | P43235 | 5/20 | 0.42 |
| ▸ | CTSB | P07858 | 4/20 | 0.42 |
| ▸ | CTSL | P07711 | 2/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6490793 | 1.00 | PTPN1 (0.42) | PTPN1CTSSCTSKCTSBCTSL | |
| SCHEMBL6488430 | 0.90 | PTPN1 (0.50) | PTPN1CTSSCTSKCTSBCTSL | |
| SCHEMBL6480495 | 0.90 | PTPN1 (0.50) | PTPN1CTSSCTSKCTSBCTSL | |
| SCHEMBL6489863 | 0.90 | PTPN1 (0.50) | PTPN1CTSSCTSKCTSBCTSL | |
| SCHEMBL6164195 | 0.77 | CTSS (0.51) | PTPN1CTSSCTSKCTSBCTSL | |
| SCHEMBL18930761 | 0.77 | CTSS (0.51) | PTPN1CTSSCTSKCTSBCTSL | |
| SCHEMBL30916035 | 0.77 | ATM (0.52) | CTSSCTSKCTSBCTSLATM | |
| SCHEMBL4728627 | 0.77 | PTPN1 (0.64) | PTPN1CTSSCTSKCTSBCTSL | |
| Hydrochloric Acid SCHEMBL6479449 | 0.76 | AKT1 (0.38) | — | |
| Hydrochloric Acid SCHEMBL6479446 | 0.76 | AKT1 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050043358-A1 | Aminoalcohol derivatives and their use as beta 3 adrenergic agonists | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2005-02-24 | — | — | US | disclosed |
| US-20020143034-A1 | Aminoalcohol derivatives and their use as beta 3 adrenergic agonists | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2002-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020143034-A1 | Aminoalcohol derivatives and their use as beta 3 adrenergic agonists | ADRB1, ADRB2, ADRB3 | PTPN1 3414/4885CTSS 4294/4885CTSK 4608/4885 |
| US-20050043358-A1 | Aminoalcohol derivatives and their use as beta 3 adrenergic agonists | ADRB2, ADRB1, ADRB3 | PTPN1 3592/4885CTSS 4072/4885CTSK 4681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.